enGene Holdings Inc. (ENGN)
ENGN Stock Price Chart
Explore enGene Holdings Inc. interactive price chart. Choose custom timeframes to analyze ENGN price movements and trends.
ENGN Company Profile
Discover essential business fundamentals and corporate details for enGene Holdings Inc. (ENGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Feb 2022
Employees
56.00
Website
https://www.engene.comCEO
Ronald H. W. Cooper
Description
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN Financial Timeline
Browse a chronological timeline of enGene Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
ENGN Stock Performance
Access detailed ENGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
